10-Q: Revvity Reports Q1 2026 Results: Revenue Up 7%, Net Income Slightly Down

Revvity, Inc. announced its first-quarter fiscal year 2026 financial results, showing a 7% increase in total revenue to $711.1 million, while net income saw a slight decrease compared to the prior year.

Summary

• Total revenue for the first quarter of fiscal year 2026 was $711.1 million, a 7% increase from $664.8 million in the first quarter of fiscal year 2025.
• This revenue growth was driven by a 6% increase in Life Sciences segment revenue to $361.8 million and an 8% increase in Diagnostics segment revenue to $349.3 million.
• Net income for the quarter was $40.7 million, a decrease from $42.2 million in the prior year's first quarter.
• Basic earnings per share from continuing operations were $0.37, up from $0.35 in the prior year.
• Diluted earnings per share from continuing operations were $0.37, up from $0.35 in the prior year.
• The company repurchased approximately $79.0 million of its common stock under its repurchase program during the quarter.
• The company expects its effective tax rate on continuing operations, before discrete items, to be approximately 20% during fiscal year 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing, with solid revenue growth offset by margin pressures and a slight dip in net income. The company's strategic investments and capital return initiatives are positive, but ongoing cost challenges and risks require attention.

Positives

• Total revenue increased by 7% to $711.1 million, driven by growth in both the Life Sciences and Diagnostics segments.
• Diagnostics segment revenue increased by 8% to $349.3 million, primarily due to growth in Reproductive Health and Immunodiagnostics.
• Life Sciences segment revenue increased by 6% to $361.8 million, driven by Life Sciences Solutions and Software businesses.
• Basic and diluted earnings per share from continuing operations increased to $0.37 from $0.35 in the prior year.
• The company has $1.5 billion in borrowing capacity available under its senior unsecured revolving credit facility.
• The company continues to return capital to shareholders through dividends ($0.07 per share declared for Q1 FY26 and Q2 FY26) and share repurchases.

Negatives

• Net income decreased to $40.7 million from $42.2 million in the prior year's first quarter.
• Consolidated gross margins decreased by 200 basis points to 54.5% due to product mix shift, foreign exchange rates, and increased tariffs.
• Consolidated operating margins decreased slightly from 10.9% to 10.7%.
• Restructuring and other costs increased significantly to $10.7 million from $3.2 million in the prior year, primarily due to workforce reductions and facility consolidations.
• Interest and other expense, net, increased to $25.9 million from $19.8 million, largely due to higher interest expense related to the extra fiscal week.

Risks

• The company's growth and profitability are subject to global economic and political conditions, including inflation, recession, and trade protectionism.
• Uncertainties surrounding government funding and regulations could reduce demand for products and services.
• Failure to introduce new products in a timely manner could lead to market share loss.
• The company may not be able to successfully execute acquisitions or integrate acquired businesses.
• Aggressive competition from numerous competitors could harm the business.
• Disruptions in third-party package delivery and import/export services could impact product shipment and increase costs.
• Supply chain disruptions from limited or single-source suppliers could adversely affect operations.
• The company faces risks related to its intellectual property, including protection and potential infringement claims.
• Product liability claims could result in substantial liability.
• Non-compliance with regulations from agencies like the FDA could lead to recalls, penalties, or cessation of distribution.
• Stringent data privacy and information security laws and regulations pose compliance risks.
• Changes in governmental regulations may reduce demand or increase expenses.
• Economic, political, and other risks associated with foreign operations could adversely affect international sales and profitability.
• A substantial amount of outstanding debt could impact the ability to obtain future financing and limit expenditures.
• Restrictive covenants in debt instruments may limit the company's activities.
• The company's share price may fluctuate significantly due to various market and operational factors.
• Dividends on common stock could be reduced or eliminated in the future.

Future Outlook

The company expects the effective tax rate on continuing operations, before discrete items, to be approximately 20% during fiscal year 2026. The Board of Directors may determine to reduce or eliminate the common stock dividend in the future to fund investments for growth, repurchase shares, or conserve capital resources.

Management Comments

• Revvity is revolutionizing whats possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
• Our overall revenue in the first quarter of fiscal year 2026 was $711.1 million which increased by $46.4 million, or 7%, as compared to the first quarter of fiscal year 2025, reflecting an increase of $24.9 million, or 8%, in our Diagnostics segment revenue, and an increase of $21.4 million, or 6%, in our Life Sciences segment revenue.
• Our consolidated gross margins decreased 200 basis points from 56.5% to 54.5% in the first quarter of fiscal year 2026, as compared to the first quarter of fiscal year 2025, primarily due to product mix shift, changes in foreign exchange rates, increased tariffs and impact of the extra fiscal week.
• Our consolidated operating margins decreased from 10.9% to 10.7% in the first quarter of fiscal year 2026, as compared to the first quarter of fiscal year 2025, primarily due to gross margin headwinds and impact of the extra fiscal week, partially offset by productivity and cost containment initiatives.

Industry Context

StockSavvy.ai notes that Revvity's performance reflects ongoing trends in the health sciences sector, with growth in diagnostics and life sciences solutions. The slight decrease in net income despite revenue growth, attributed to factors like product mix, foreign exchange, tariffs, and increased restructuring costs, highlights the margin pressures and operational complexities common in this industry.

Comparison to Industry Standards

• Revvity's revenue growth of 7% in Q1 FY26 is a solid performance, particularly within the health sciences and diagnostics sectors, which have seen varied growth rates among competitors. For instance, Thermo Fisher Scientific reported a 1% revenue decline in its most recent quarter, while Danaher's life sciences segment showed modest growth.
• The gross margin decline of 200 basis points, attributed to product mix, foreign exchange, tariffs, and an extra fiscal week, is a key area to monitor. Many companies in the sector are facing similar pressures from supply chain costs and currency fluctuations. For example, Agilent Technologies has also cited foreign exchange headwinds impacting its margins.
• The increase in restructuring costs is a common theme as companies streamline operations in response to evolving market conditions. This is also observed in companies like PerkinElmer, which has undertaken restructuring initiatives.
• Revvity's effective tax rate of 18.2% for the quarter is within the expected range for companies in the sector, though slightly lower than the prior year's 20.5% due to specific tax adjustments.

Corporate Governance

Legal Proceedings

• The company is subject to various claims, legal proceedings, and investigations arising in the ordinary course of business, including product liability claims. Management believes the total cost of resolving these contingencies should not have a material adverse effect on the financial statements, though uncertainties exist.
• The company is conducting environmental investigations and remedial actions and has been named a potentially responsible party for certain waste disposal sites. Accruals have been made for estimated remediation costs.

Stakeholder Impact

• Shareholders: The slight decrease in net income and potential for dividend reduction could impact shareholder returns, while share repurchases may support share value. Stock price volatility remains a concern.
• Employees: Restructuring actions affecting approximately 2% of the workforce indicate potential job impacts.
• Customers: Continued innovation and product development are crucial to meet evolving customer needs in the life sciences and diagnostics sectors.
• Suppliers: The company relies on a wide variety of raw materials and components, with some from limited or single-source suppliers, posing a risk to the supply chain.

Next Steps

• Continue to monitor the impact of product mix shifts, foreign exchange rates, and tariffs on gross margins.
• Evaluate the effectiveness of restructuring and cost containment initiatives.
• Assess the progress of new product development and commercialization efforts.
• Monitor the company's share repurchase program and dividend declarations.
• Observe the company's response to evolving regulatory landscapes in the healthcare and data privacy sectors.

Key Dates

Recommendation

Revvity's Q1 FY26 results show solid revenue growth, but margin pressures and a slight decrease in net income warrant a cautious approach. While the company is investing in growth and returning capital, ongoing challenges related to product mix, foreign exchange, tariffs, and restructuring costs suggest a 'hold' recommendation until these pressures ease and profitability trends stabilize.

Keywords

Revvity, 10-Q, Quarterly Report, Life Sciences, Diagnostics, Revenue, Net Income, Earnings Per Share, Financial Results, Healthcare Technology, Acquisition, Share Repurchase